Michael Salmon
- The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosingBy Dramane I. Lainé, Mark A. Luttmann, James J. Foley, Chris J. Dehaas, Charles J. Kotzer, Michael Salmon and William L. RumseyDramane I. LainéRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesMark A. LuttmannRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesJames J. FoleyRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesChris J. DehaasRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesCharles J. KotzerRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesMichael SalmonRespiratory CEDD, GlaxoSmithKline, King of Prussia, United StatesWilliam L. RumseyRespiratory CEDD, GlaxoSmithKline, King of Prussia, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.